NASDAQ:CYTK Cytokinetics (CYTK) Stock Price, News & Analysis $59.69 +1.19 (+2.03%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$58.58▼$61.3750-Day Range$47.86▼$60.6052-Week Range$25.98▼$110.25Volume1.17 million shsAverage Volume2.53 million shsMarket Capitalization$6.26 billionP/E RatioN/ADividend YieldN/APrice Target$77.06 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Cytokinetics alerts: Email Address Cytokinetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside29.1% Upside$77.06 Price TargetShort InterestBearish15.75% of Float Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.86Based on 10 Articles This WeekInsider TradingSelling Shares$7.81 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.50) to ($4.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.25 out of 5 starsMedical Sector160th out of 936 stocksPharmaceutical Preparations Industry66th out of 436 stocks 4.4 Analyst's Opinion Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 15 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageCytokinetics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cytokinetics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.75% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Cytokinetics has recently increased by 0.46%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytokinetics has received a 71.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cytokinetics is -0.83. Previous Next 2.7 News and Social Media Coverage News SentimentCytokinetics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Cytokinetics this week, compared to 8 articles on an average week.Search InterestOnly 8 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,814,083.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Cytokinetics is held by insiders.Read more about Cytokinetics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($4.50) to ($4.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -11.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -11.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cytokinetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Cytokinetics Stock (NASDAQ:CYTK)Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Read More CYTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTK Stock News HeadlinesJuly 24 at 5:24 AM | insidertrades.comCytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 7,300 SharesJuly 17, 2024 | insidertrades.comCytokinetics, Incorporated (NASDAQ:CYTK) Director B Lynne Parshall Sells 5,000 SharesJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 12, 2024 | insidertrades.comRobert I. Blum Sells 11,500 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockJuly 11, 2024 | insidertrades.comFady Ibraham Malik Sells 7,300 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockJuly 10, 2024 | insidertrades.comInsider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 7,300 Shares of StockJuly 9, 2024 | insidertrades.comCytokinetics, Incorporated (NASDAQ:CYTK) Director Sells $13,816.33 in StockJuly 2, 2024 | insidertrades.comInsider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells 5,000 Shares of StockJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 25 at 4:00 PM | globenewswire.comCytokinetics to Announce Second Quarter Results on August 8, 2024July 24 at 8:00 AM | seekingalpha.comCytokinetics' Aficamten: Heartfelt Potential Amid Market WoesJuly 23 at 1:27 AM | americanbankingnews.comHead to Head Comparison: Cytokinetics (NASDAQ:CYTK) and CannaPharmaRX (OTCMKTS:CPMD)July 18, 2024 | americanbankingnews.comB Lynne Parshall Sells 5,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockJuly 10, 2024 | gurufocus.comInsider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)July 3, 2024 | globenewswire.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 2, 2024 | gurufocus.comInsider Sale: Director B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK)June 17, 2024 | globenewswire.comCytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese ParticipantsJune 4, 2024 | globenewswire.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYTK CUSIPN/A CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees423Year Founded1997Price Target and Rating Average Stock Price Target$77.06 High Stock Price Target$106.00 Low Stock Price Target$50.00 Potential Upside/Downside+29.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)($5.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-526,240,000.00 Net Margins-14,141.74% Pretax Margin-14,141.74% Return on EquityN/A Return on Assets-67.32% Debt Debt-to-Equity RatioN/A Current Ratio7.19 Quick Ratio7.19 Sales & Book Value Annual Sales$7.53 million Price / Sales831.14 Cash FlowN/A Price / Cash FlowN/A Book Value($3.94) per share Price / Book-15.15Miscellaneous Outstanding Shares104,850,000Free Float101,289,000Market Cap$6.26 billion OptionableOptionable Beta0.75 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Robert I. Blum (Age 60)CEO, President, Principal Financial Officer & Director Comp: $1.33MMr. Robert C. Wong (Age 56)VP & Chief Accounting Officer Comp: $495.72kDr. Fady Ibraham Malik FACC (Age 60)M.D., Ph.D., Executive Vice President of Research & Development Comp: $839.66kMr. Andrew M. Callos (Age 55)Executive VP & Chief Commercial Officer Comp: $752.84kDr. James A. Spudich Ph.D. (Age 82)Co-Founder & Member of Scientific Advisory Board Comp: $21.94kMr. Jeff LotzVice President of Sales & OperationsMr. Matt YangVice President of Corporate Finance and Financial Planning & AnalysisMr. Steven M. Cook (Age 65)Senior Vice President of Global Supply Chain Operations & Technical Operations Ms. Kari K. Loeser J.D.VP & Chief Compliance OfficerMr. John O. Faurescu Esq.VP, Associate General Counsel & Corporate SecretaryMore ExecutivesKey CompetitorsConstellation PharmaceuticalsNASDAQ:CNSTZogenixNASDAQ:ZGNXIntercept PharmaceuticalsNASDAQ:ICPTORIC PharmaceuticalsNASDAQ:ORICPhathom PharmaceuticalsNASDAQ:PHATView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 84,396 shares on 7/26/2024Ownership: 0.084%State of Michigan Retirement SystemBought 3,500 shares on 7/26/2024Ownership: 0.026%Summit Securities Group LLCSold 4,200 shares on 7/26/2024Ownership: 0.021%Legato Capital Management LLCBought 4,380 shares on 7/26/2024Ownership: 0.004%Louisiana State Employees Retirement SystemBought 4,200 shares on 7/24/2024Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions CYTK Stock Analysis - Frequently Asked Questions How have CYTK shares performed this year? Cytokinetics' stock was trading at $83.49 at the start of the year. Since then, CYTK stock has decreased by 28.5% and is now trading at $59.69. View the best growth stocks for 2024 here. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) released its quarterly earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing analysts' consensus estimates of ($1.16) by $0.17. Cytokinetics's quarterly revenue was down 81.8% on a year-over-year basis. What is Robert I. Blum's approval rating as Cytokinetics' CEO? 16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees. Who are Cytokinetics' major shareholders? Top institutional shareholders of Cytokinetics include Retirement Systems of Alabama (0.13%), Allspring Global Investments Holdings LLC (0.08%), Mirador Capital Partners LP (0.06%) and Louisiana State Employees Retirement System (0.03%). Insiders that own company stock include Robert I Blum, Fady Ibraham Malik, Ching Jaw, John T Henderson, B Lynne Parshall, Wendall Wierenga, Muna Bhanji, Robert Wong, Robert Arthur Harrington, Santo J Costa, Edward M Md Kaye, Mark A Schlossberg, L Patrick Gage, David Cragg and Sandford D Smith. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO) and Sorrento Therapeutics (SRNE). This page (NASDAQ:CYTK) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.